Free Trial

Upexi (UPXI) Competitors

Upexi logo
$5.39 +0.39 (+7.80%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$5.36 -0.03 (-0.65%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UPXI vs. PGEN, SIGA, ATYR, ORKA, CAPR, CGEM, MREO, KMDA, RAPP, and RGNX

Should you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Precigen (PGEN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Oruka Therapeutics (ORKA), Capricor Therapeutics (CAPR), Cullinan Therapeutics (CGEM), Mereo BioPharma Group (MREO), Kamada (KMDA), Rapport Therapeutics (RAPP), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

Upexi vs. Its Competitors

Precigen (NASDAQ:PGEN) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 47.1% of Precigen shares are owned by company insiders. Comparatively, 31.6% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Precigen currently has a consensus target price of $6.00, indicating a potential upside of 227.87%. Upexi has a consensus target price of $16.00, indicating a potential upside of 196.85%. Given Precigen's higher probable upside, equities analysts clearly believe Precigen is more favorable than Upexi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precigen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Upexi
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Upexi has a net margin of -135.86% compared to Precigen's net margin of -3,728.87%. Precigen's return on equity of -279.20% beat Upexi's return on equity.

Company Net Margins Return on Equity Return on Assets
Precigen-3,728.87% -279.20% -79.74%
Upexi -135.86%-535.19%-122.94%

Upexi has higher revenue and earnings than Precigen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precigen$3.92M137.80-$126.24M-$0.56-3.27
Upexi$26M7.86-$23.66MN/AN/A

Precigen has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.58, suggesting that its share price is 158% less volatile than the S&P 500.

In the previous week, Precigen and Precigen both had 6 articles in the media. Precigen's average media sentiment score of 1.27 beat Upexi's score of 0.61 indicating that Precigen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Precigen
2 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Upexi
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Precigen beats Upexi on 9 of the 12 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPXI vs. The Competition

MetricUpexiTechnology Services IndustryBusiness SectorNASDAQ Exchange
Market Cap$204.36M$2.42B$15.36B$9.10B
Dividend YieldN/A1.44%2.72%4.02%
P/E RatioN/A30.8828.6920.26
Price / Sales7.8634.61430.63153.06
Price / CashN/A43.4826.3457.67
Price / Book0.865.836.185.49
Net Income-$23.66M$32.23M$190.21M$250.45M
7 Day Performance65.08%2.33%0.97%4.79%
1 Month Performance-46.15%9.96%6.08%9.59%
1 Year Performance-39.44%39.12%28.16%16.41%

Upexi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPXI
Upexi
2.6332 of 5 stars
$5.39
+7.8%
$16.00
+196.8%
-39.4%$204.36M$26M0.00130News Coverage
Gap Up
High Trading Volume
PGEN
Precigen
4.107 of 5 stars
$1.59
-1.9%
$6.00
+277.4%
+13.7%$478.19M$4.20M-2.84190Positive News
Analyst Upgrade
SIGA
Siga Technologies
2.246 of 5 stars
$6.73
+0.6%
N/A-22.4%$477.94M$138.72M10.0440News Coverage
Options Volume
ATYR
aTyr Pharma
2.0952 of 5 stars
$5.30
-0.2%
$20.20
+281.1%
+204.6%$472.61M$230K-6.5453Gap Down
High Trading Volume
ORKA
Oruka Therapeutics
2.9071 of 5 stars
$13.29
+5.5%
$40.38
+203.8%
N/A$471.75MN/A-2.95N/APositive News
CAPR
Capricor Therapeutics
2.5454 of 5 stars
$9.90
-3.4%
$32.22
+225.5%
+73.6%$468.19M$22.27M-6.97101Trending News
Analyst Forecast
Gap Down
CGEM
Cullinan Therapeutics
1.6897 of 5 stars
$7.42
-5.0%
$30.00
+304.3%
-53.2%$460.90MN/A-2.5530News Coverage
MREO
Mereo BioPharma Group
1.5651 of 5 stars
$2.92
+1.7%
$7.60
+160.3%
-61.2%$456.33M$10M-41.7140News Coverage
Analyst Forecast
Gap Up
High Trading Volume
KMDA
Kamada
4.2241 of 5 stars
$7.71
-2.2%
$13.00
+68.6%
+24.8%$453.14M$167.24M26.59360
RAPP
Rapport Therapeutics
1.8152 of 5 stars
$12.04
flat
$28.00
+132.6%
-43.1%$439.43MN/A-3.49N/ANews Coverage
Analyst Forecast
RGNX
REGENXBIO
4.0438 of 5 stars
$8.43
-3.5%
$31.63
+275.1%
-32.0%$438.40M$83.33M-2.71370News Coverage

Related Companies and Tools


This page (NASDAQ:UPXI) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners